Literature DB >> 12414661

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Takashi Kijima1, Gautam Maulik, Patrick C Ma, Elena V Tibaldi, Ross E Turner, Barrett Rollins, Martin Sattler, Bruce E Johnson, Ravi Salgia.   

Abstract

The regulation of biological functions including cell growth, viability, migration, and adhesion of small cell lung cancer (SCLC) cells depends largely on the autocrine or paracrine stimulation of growth factor receptors and chemokine receptors. Stem cell factor (SCF) and its receptor c-Kit have been identified as important regulators of SCLC viability and are coexpressed in approximately 40-70% of SCLC specimens. In vitro, the inhibition of c-Kit tyrosine kinase activity by the small molecule tyrosine kinase inhibitor STI571 (Gleevec) abrogates cell growth. We have investigated the role of c-Kit and chemokine receptors in the regulation of cell migration and adhesion of SCLC cells. CXCR4, the chemokine receptor for stromal cell-derived factor-1alpha (SDF-1alpha), was found to be the major chemokine receptor commonly expressed in all of the 10 SCLC cell lines tested. SCF and SDF-1alpha increased cellular proliferation over a course of 72 h in both the c-Kit- and the CXCR4-positive NCI-H69 SCLC cell line. Recently, SDF-1alpha and CXCR4 have been shown to be important regulators of migration and metastasis in breast and ovarian cancer. We found that SDF-1alpha dramatically increased cell motility and adhesion in CXCR4-expressing NCI-H446 SCLC cells. In addition, SDF-1alpha altered cell morphology with increased formation of filopodia and neurite-like projections. In NCI-H69 SCLC cells, SCF and SDF-1alpha cooperatively induced morphological changes and activated downstream signaling pathways. Treatment of NCI-H69 cells with STI571 specifically inhibited the c-Kit signaling events of Akt and p70 S6 kinase, whereas SDF-1alpha-mediated activation of Akt or p70 S6 kinase was normal. In contrast, the phosphatidylinositol 3-kinase inhibitor, LY294002, prevented these cells from adhering and completely blocked SCF- and/or SDF-1alpha-induced Akt or p70 S6 kinase phosphorylation. These results demonstrate that the CXCR4 receptor is functionally expressed in SCLC cells and may, therefore, be involved in the pathogenesis of SCLC in vivo. Inhibition of both the CXCR4 and the c-Kit downstream events could be a promising therapeutic approach in SCLC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  [68Ga-pentixafor PET: clinical molecular imaging of chemokine receptor CXCR4 expression in multiple myeloma].

Authors:  M Avanesov; M Karul; T Derlin
Journal:  Radiologe       Date:  2015-10       Impact factor: 0.635

Review 3.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 4.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

5.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

Authors:  Joshua B Rubin; Andrew L Kung; Robyn S Klein; Jennifer A Chan; YanPing Sun; Karl Schmidt; Mark W Kieran; Andrew D Luster; Rosalind A Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

6.  The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.

Authors:  Rubén A Bartolomé; Sergio Ferreiro; María E Miquilena-Colina; Lorena Martínez-Prats; María L Soto-Montenegro; David García-Bernal; Juan J Vaquero; Reuven Agami; Rafael Delgado; Manuel Desco; Paloma Sánchez-Mateos; Joaquin Teixidó
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 7.  CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion.

Authors:  Magda Kucia; Kacper Jankowski; Ryan Reca; Marcin Wysoczynski; Laura Bandura; Daniel J Allendorf; Jin Zhang; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 8.  The role of the CXCR4 cell surface chemokine receptor in glioma biology.

Authors:  Moneeb Ehtesham; Elliot Min; Neil M Issar; Rebecca A Kasl; Imad S Khan; Reid C Thompson
Journal:  J Neurooncol       Date:  2013-03-14       Impact factor: 4.130

9.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

10.  Alteration of podocytes in a murine model of crescentic glomerulonephritis.

Authors:  Valérie Besse-Eschmann; Michel Le Hir; Nicole Endlich; Karlhans Endlich
Journal:  Histochem Cell Biol       Date:  2004-08       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.